CD’X (about 5.5%) in a distribution agreement with a testing laboratory in the USA for the detection of prostate cancer using IsoPSA Post published:25/12/2022
CD’X (about 5.5%) received approval from an American health insurer to cover the use of IsoPSA for the early diagnosis of prostate cancer Post published:11/10/2022
Nerview (7.63%) will invest 300 A$ in Medipress against an allocation of about 3.27% in Medipress Post published:27/07/2022
Ocon Medical’s engagement (approximately 10%) in understandings for licensing and business cooperation with a Chinese pharma company Post published:23/06/2022
Negotiations for the merger agreement ended without it maturing into a binding agreement Post published:28/02/2022
Memorandum of Understanding does not require licensing and cooperation between Okon Medical (10.2%) and Chinese Pharma Post published:23/01/2022
